[1]侯文渊,朱磊,顾一帆,等.骨痹通消颗粒治疗早中期非创伤性股骨头坏死38例[J].中国中医骨伤科杂志,2023,31(01):56-60.
　HOU Wenyuan,ZHU Lei,GU Yifan,et al.38 Cases of Clinical Study on Gubi Tongxiao Granules on the Treatment of Patients with Non-Traumatic Femoral Head Necrosis in Early and Middle Stages[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2023,31(01):56-60.
点击复制

骨痹通消颗粒治疗早中期非创伤性股骨头坏死38例()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第31卷
期数:
2023年01期
页码:
56-60
栏目:
临床报道
出版日期:
2023-01-15

文章信息/Info

Title:
38 Cases of Clinical Study on Gubi Tongxiao Granules on the Treatment of Patients with Non-Traumatic Femoral Head Necrosis in Early and Middle Stages
文章编号:
1005-0205(2023)01-0056-05
作者:
侯文渊1; 朱磊2; 顾一帆2; 朱彩玉1; 周正新2△
1安徽中医药大学(合肥,230031) 2安徽中医药大学第一附属医院
Author(s):
HOU Wenyuan1; ZHU Lei2; GU Yifan2; ZHU Caiyu1; ZHOU Zhengxin2△
1Anhui University of Chinese Medicine, Hefei 230031,China; 2The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031,China.
关键词:
非创伤性股骨头坏死;  早中期;  骨痹通消颗粒;  回顾性研究
Keywords:
non-traumatic femoral head necrosis;  Gubi Tongxiao granules;  early and middle stage;  retrospective study
分类号:
R681.8
文献标志码:
B
摘要:
目的:回顾性分析骨痹通消颗粒治疗早中期非创伤性股骨头坏死的临床疗效及安全性。方法:选取2020年1月至2020年12月收治的早中期非创伤性股骨头坏死患者38例,使用骨痹通消颗粒进行治疗,分别于治疗前、治疗后3个月和治疗后1年评估患者的视觉模拟量表(VAS)疼痛评分、Harris髋关节评分、X线片评分及安全性。结果:所有患者治疗期间未出现严重不良反应。治疗3个月及治疗1年时患者VAS疼痛评分较治疗前明显降低,差异有统计学意义(P<0.05)。治疗3个月及治疗1年时Harris评分较治疗前持续改善,差异有统计学意义(P<0.05)。对比治疗1年和治疗前的双髋关节正位片、蛙位片差异无统计学意义(P>0.05)。结论:使用骨痹通消颗粒治疗早中期非创伤性股骨头坏死临床疗效可靠,具有较高的安全性。
Abstract:
Objective:To analyze the clinical efficacy and safety of Gubi Tongxiao granules on the treatment of early and middle stage non-traumatic osteonecrosis of femoral head.Methods:38 cases of patients with early and middle stage non-traumatic femoral head necrosis from January 2020 to December 2020 were selected and treated with Gubi Tongxiao granules.Visual analogue scale(VAS)pain score, Harris hip score, radiographic X-ray score and safety of patients were evaluated before treatment, 3 months, and 1 year after treatment.Results:No serious adverse reactions occurred in all patients during treatment. After 3 months of treatment and 1 year of treatment, the VAS pain scores of the patients were significantly lower than those before treatment, and the difference were statistically significant(P<0.05). The Harris score continued to improve after 3 months of treatment and 1 year after treatment, and the difference was statistically significant(P<0.05). There was no significant difference in the anteroposterior radiographs and frog radiographs of both hips after 1 year of treatment and before treatment, so the difference was not statistically significant(P>0.05).Conclusion:The use of Gubi Tongxiao granules on the treatment of early and middle stage non-traumatic femoral head necrosis has reliable clinical efficacy and higher safety.

参考文献/References:

[1] TAN B,LI W,ZENG P,et al.Epidemiological study based on china osteonecrosis of the femoral head database[J].Orthopaedic Surgery,2021,13(1):153-160.
[2] DHANASEKARARAJA P,SOUNDARRAJAN D,KUMAR K S,et al.Aggressive presentation and rapid progression of osteonecrosis of the femoral head after COVID-19[J].Indian Journal of Orthopaedics,2022,56(7):1259-1267.
[3] SA KAI T,UESUGI Y,SEKI T,et al.Quality of life of patients with osteonecrosis of the femoral head:a multicentre study[J].International Orthopaedics,2018,42(7):1517-1525.
[4] 韩士鼎,朱磊,周正新,等.中药骨痹通消颗粒联合髓芯减压植骨术治疗ARCOⅠ-Ⅱ期股骨头坏死临床疗效观察[J].中医药临床杂志,2021,33(8):1559-1562.
[5] 中华中医药学会.股骨头坏死中医辨证标准(2019年版)[J].中医正骨,2019,31(6):1-2.
[6] 中国医师协会骨科医师分会骨循环与骨坏死专业委员会,中华医学会骨科分会骨显微修复学组,国际骨循环学会中国区.中国成人股骨头坏死临床诊疗指南(2020)[J].中华骨科杂志,2020,40(20):1365-1376.
[7] CHIAROTTO A,MAXWELL L J,OSTELO R W,et al.Measurement properties of visual analogue scale,numeric rating scale,and pain severity subscale of the brief pain inventory in patients with low back pain:a systematic review[J].The Journal of Pain,2019,20(3):245-263.
[8] WEICK J W,BULLARD J,GREEN J H,et al.Measures of hip function and symptoms[J].Arthritis Care & Research,2020,72(Suppl 10):200-218.
[9] 陈卫衡.基于X线的股骨头坏死保髋疗效评价方法研究[J].中华关节外科杂志(电子版),2017,11(3):222-227.
[10] MONT M A,SALEM H S,PIUZZI N S,et al.Nontraumatic osteonecrosis of the femoral head:where do we stand today?A 5-year update[J].The Journal of Bone and Joint Surgery:American Volume,2020,102(12):1084-1099.
[11] ZHAO D,ZHANG F,WANG B,et al.Guidelines for clinical diagnosis and treatment of osteonecrosis of the femoral head in adults(2019 version)[J].Journal of Orthopaedic Translation,2020,21:100-110.
[12] 陈瑞,康武林,董博,等.刘德玉论治股骨头坏死经验浅谈[J].中国中医骨伤科杂志,2020,28(11):72-73.
[13] 尹啸飞,周正新.中医药治疗股骨头坏死临床研究进展[J].辽宁中医药大学学报,2018,20(2):218-221.
[14] 朱诗白,张啸天,陈曦,等.股骨头坏死的保髋治疗[J].中华关节外科杂志(电子版),2020,14(6):741-746.
[15] LIU N,ZHENG C,WANG Q,et al.Treatment of non-traumatic avascular necrosis of the femoral head(Review)[J].Experimental and Therapeutic Medicine,2022,23(5):321.
[16] 袁雪超,路玉峰,鲁超,等.龙元通络生骨颗粒治疗早期激素性股骨头坏死40例[J].中国中医骨伤科杂志,2021,29(3):70-74.
[17] 李欢欢,李军,张伪松,等.通络生骨方治疗股骨头骨髓水肿综合征的前瞻性临床研究[J].中国中医骨伤科杂志,2019,27(7):27-31.
[18] 乌日莎娜,陈哓俊,沈莹姗,等.活血通络胶囊通过OPG/RANKL/PDGF-BB通路对激素性股骨头坏死模型大鼠的干预作用[J].中药新药与临床药理,2022,33(4):433-440.
[19] 孙墨渊,杨光耀,张蕾蕾,等.股骨头坏死愈胶囊联合头颈部开窗打压植骨治疗非创伤性股骨头坏死的临床疗效观察[J].中国中医骨伤科杂志,2022,30(6):42-47.
[20] 姜珊,王少平,代龙,等.土鳖虫活性肽组分对急性血瘀模型大鼠血液流变学、血脂四项指标及血液因子含量的影响[J].食品与机械,2020,36(1):175-180.
[21] 黄海涛,叶攀.丹参川芎嗪注射液治疗脑血栓对患者脑血流动力学水平和凝血功能影响[J].时珍国医国药,2019,30(4):917-919.
[22] 李伟霞,王晓艳,唐进法,等.基于PLS-DA和多指标综合指数法研究当归-川芎药对对急性血瘀大鼠血清中血管活性物质和黏附分子的影响[J].药学学报,2019,54(11):1909-1917.
[23] 程江雪,唐志书,郭东艳,等.当归-赤芍配伍对热毒血瘀证模型大鼠的影响[J].中国现代应用药学,2019,36(23):2894-2898.
[24] 袁子文,钟立甲,纪鹏,等.当归干预血瘀证大鼠血浆代谢组学研究[J].天然产物研究与开发,2018,30(4):559-567.
[25] 黄为,董盼锋,黄有荣,等.淫羊藿调控骨髓间充质干细胞分化防治骨质疏松的相关信号通路[J].中国组织工程研究,2022,26(30):4889-4895.
[26] 赵金龙,梁桂洪,韩燕鸿,等.川续断提取物续断皂苷Ⅵ防治骨质疏松症的研究进展[J].中国骨质疏松杂志,2020,26(5):755-759.
[27] 王晓艳,李伟霞,张辉,等.五味子-甘草配伍的调血脂作用及对甘油三酯合成途径的影响[J].中国药理学通报,2021,37(1):136-142.
[28] 何晓铭,沈莹姗,庞凤祥,等.股骨头坏死患者血瘀证诊断指标的临床调查研究[J].中华中医药杂志,2022,37(1):328-332.

备注/Memo

备注/Memo:
基金项目:安徽省自然科学基金面上项目(2008085MH281)
△通信作者 E-mail:zhouzhengxin1968@sina.com
更新日期/Last Update: 2023-01-10